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Abstract
This note examines the EU’s efforts to regulate gene therapy, considering the Union’s resolve
to establish scientifically, economically, and morally sound parameters acceptable to its varied
constituency. This includes discussion of legal and ethical considerations, biotechnology goals in
the EU, and EU-wide uniform regulations.
THE DEVELOPMENT OF REGULATORY STANDARDS FOR
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INTRODUCTION
In the more than forty years since James Watson and Francis
Crick discovered the structure of Deoxyribonucleic Acid'
("DNA") in 1953,2 researchers have made formidable advances
in molecular genetics.3 Scientists have accumulated enough
knowledge to begin to apply in human subjects the techniques
of genetic manipulation 4 developed in animal trials.5 This tran-
sition has opened a new field of research that is at once promis-
* J.D. Candidate, 1996, Fordham University. The 1994 MCI-Fordham
International Law Fellowship generously funded the research for this Note. The
Author would like to thank Ms. Isabelle Arnal, Secretary, European Union Ethical
Committee on Biotechnology.
1. JAMES D. WATSON, THE DOUBLE HELIX: A PERSONAL AccouNT OF THE DIScovERY
OF THE STRucruRE OF DNA (1968) [hereinafter WATSON, THE DOUBLE HELIX]; James D.
Watson & Francis Crick, Genetical Implications of the Structure of Deoxyribonuceic Acid, 171
NATURE 964 (1953). Deoxyribonucleic Acid is a type of nucleic acid found principally
in the nuclei of animal and vegetable cells that is considered to be the repository of
hereditary characteristics. Id.
2. See WATSON, THE DOUBLE HEtLX, supra note 1 (including basic scientific back-
ground).
3. LouisJ. Elsas II, A Clinical Approach to Legal and Ethical Problems in Human Genet-
ics, 39 EMORY L.J. 811, 812 (1990) [hereinafter Clinical Approach]; seeJAMEs D. WATSON
ET AL., RECOMBINANT DNA (2d ed. 1992) [hereinafter RECOMBINANT DNA] (describing
advances in genetic research).
Even though genetic counseling and prenatal diagnosis are invaluable for fam-
ilies who are known to have an inherited disorder, there exists a long-cher-
ished hope that patients already afflicted might be treated by replacing their
defective gene with the normal gene. For many years this project seemed to
be very remote, more aptly belonging to the realms of science fiction. Only
with the application of recombinant DNA techniques to human genetic dis-
eases did research to develop practicable methods of gene therapy become
possible.
Id. at 567.
4. David A. Kessler et al., Regulation of Somatic-Cell Therapy and Gene Therapy by the
Food and Drug Administration, 329 NEw ENG. J. MED. 1169 (1993) [hereinafter Kessler,
Regulation].
5. See id. at 1171 (discussing testing in animals in investigational phases of gene
therapy); John C. Fletcher, Moral Problems and Ethical Issues in Prospective Human Gene
Therapy, 69 VA. L. REv. 515, 528-29 (1983) [hereinafter Fletcher, Moral Problems] (dis-
cussing widely-accepted practice of experimentation on animals to assess risks and ben-
efits of experimentation on humans).
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ing and controversial: gene therapy.6 Gene therapy involves the
manipulation of genetic material to diagnose, prevent, or treat
disease.7 Through the efforts of researchers around the world,
scientific advances in the past decade have made clinical testing
of gene therapy a reality.8 This new technology further allows
the rapid development of products for a variety of applications,
including use as vaccines,9 diagnostic agents,10 drug-delivery sys-
tems,'1 and treatment for malignant, infectious, and genetic dis-
eases.12 Various approaches, at different stages of testing, are
being investigated to treat cystic fibrosis, atherosclerosis,
hemophilia, cancer, and chronic infections such as Human Im-
munodeficiency Virus ("HIV") 3
Gene therapy, while having tremendous medical and eco-
nomic potential, is also controversial.14 Public resistance to gene
therapy can be great given real or perceived possibilities for
abuse or harm inherent in this technology. 5 The concept of
genetic manipulation also conflicts with certain national and cul-
tural norms.1 6 Thus, individual nations in which gene therapy
research is conducted have realized the need to regulate the
6. GROUP OF ADVISERS ON ETHICAL IMPLICATIONS OF BIOTECHNOLOGY OF THE EURO-
PEAN COMMISSION, REPORT ON ETHICAL ASPECTS OF GENE THERAPY 1 (1994) [hereinafter
ARCHER REPORT]. "Human gene therapy is the deliberate transfer of genetic material
into a patient's cells with the purpose of curing or preventing a disease." Id.; see DEP'T
OF HEALTH AND HUMAN SERVICES, MEMORANDUM (1991). "Gene therapy is a medical
intervention based on modification of the genetic material of living cells." Id. at 3.
7. Kessler, Regulation, supra note 4, at 1169; see ARCHER REPORT, supra note 6, at 1
(defining gene therapy).
8. W. French Anderson, Human Gene Therapy, 256 ScL 808, 809 (1992) [hereinaf-
ter Human GT]. "Human gene therapy has progressed from speculation to reality in a
short time." Id.
9. Kessler, Regulation, supra note 4, at 1169. Vaccines are any preparation in-
tended for active immunological prophylaxis. Id.
10. See id. Diagnostic agents are devices or techniques used to determine the na-
ture of a disease. Id.
11. See id. Drug-delivery systems are means or techniques devised to distribute
therapeutic agents. Id.
12. See id. Examples of these types of diseases are, respectively, cancer, Human
Immunodeficiency Virus ("HIV"), and hemophilia. Id.
13. Id.
14. RECOMBINANT DNA, supra note 3, at 569; see Human GT, supra note 8, at 812
(discussing promise and controversy inherent in gene therapy).
15. LeRoy Walters, The Ethics of Human Gene Therapy, 320 NATURE 225 (1986)
[hereinafter Ethics].
16. Id.
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field. 7 The European Union ("Union" or "EU"), is however, has
not enacted specific legislation regulating gene therapy re-
search. 9 As in other leading technological fields, the success of
the Union in gene therapy depends upon its ability to harmo-
nize its research efforts. ° The Union, therefore, must balance
these concerns in elaborating gene therapy regulations, while
also trying to remain competitive globally.
This Note examines the European Union's efforts to regu-
late gene therapy, considering the Union's resolve to establish
scientifically, economically, and morally sound parameters ac-
ceptable to its varied constituency. Part I provides the scientific
background on gene therapy, examines the legal and ethical is-
sues that gene therapy raises, and considers current regulatory
frameworks. Part II examines the goals of the European Com-
mission in biotechnology as set out in Growth, Competitiveness, Em-
ployment: The Challenges and Ways Forward Into the 21st Centuiy,
White Papers1 ("White Pape?') and the recommendations of the
Group of Advisers on the Ethical Implications of Biotechnology
presented in the Report on Ethical Aspects of Gene Therapy22 ("Archer
Report"). Part III stresses the importance of Union-wide regula-
17. Alexander Morgan Capron, Which Ills to Bear?: Reevaluating the "Threat" of Mod-
ern Genetics, 39 EMORY L.J. 665; 671 (1990) [hereinafter Capron, .Threat"].
18. See Treaty Establishing the European Community, Feb. 7, 1992, [1992] 1
C.M.L.R. 573 [hereinafter EC Treaty], incorporating changes made by Treaty on European
Union, Feb. 7, 1992, O.J. C 224/1 (1992), [1992] 1 C.M.L.R. 719, 31 I.L.M. 247 [herein-
after TEU]. The TEU, supra, amended the Treaty Establishing the European Economic
Community, Mar. 25, 1957, 298 U.N.T.S. 11, 1973 Gr. Brit. T.S. No. 1 (Cmd. 5179-I)
[hereinafter EEC Treaty], as amended by Single European Act, OJ. L 169/1 (1987),
[1987] 2 C.M.L.R. 741 [hereinafter SEA], in TREATIES ESTABLISHING THE EUROPEAN
COMMUNrTES (EC Off'l Pub. Off. 1987). Until 1995, the twelve EU Member States were
Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Luxembourg, the Nether-
lands, Portugal, Spain, and the United Kingdom. TEU, supra, pmbl. On January 1,
1995, Austria, Finland, and Sweden became Member States of the European Union. See
Hugh Carnegy, Sweden Gives Clear Yes to EU Vote in Favour of Membership Keeps Enlarge-
ment Timetable on Course, FIN. TIMES, Nov. 14, 1994, at 1 (discussing accession of new
states). The enlarged Union does not include Norway, which rejected membership in
the Union in November 1994. John Darton, Vote in Norway BlocksJoining Europe's Union,
N.Y. TIMES, Nov. 29, 1994, at Al.
19. ARCHER REPORT, supra note 6, at 8.
20. See BERMuAN ET AL., CASES AND MATERIALS ON EUROPEAN COMMUNITY LAW (1992)
[hereinafter EC LAw].
21. Commission of the European Communities, Growth, Competitiveness, Em-
ployment: The Challenges and Ways Forward Into the 21st Century, White Paper,
COM (93) 700 Final (1993) [hereinafter White Paper].
22. ARCHER REPORT, supra note 6.
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tion of research and clinical efforts in gene therapy and warns
that lest the Union fully carry out its goals of coordination and
harmonization,"3 it will be putting itself at a competitive disad-
vantage in the field of gene therapy. This Note concludes that
the Union will jeopardize its chances of exploiting the full po-
tential of a promising new technology should it fail to articulate
uniform gene therapy regulations.
I. APPLICATIONS AND IMPLICATIONS OF GENE THERAPY:
AN OVERVIEW
Modem advances in biotechnology have allowed scientists
to develop protocols2 4 to treat genetic diseases in humans by re-
placing defective genes with functional ones through gene ther-
apy.2 '5 Thus, the results of gene therapy research have yielded
medical applications that are presently being used.26 Given the
potential for abuse inherent in the technology, however, the
legal and ethical issues raised by the field of gene therapy are as
great as its promise.27 A delicate balance must therefore be
struck between the progress of scientists and the management of
risks.2 Current regulatory frameworks at different levels within
the European Union manage various aspects of gene therapy re-
search. 9
A. Gene Therapy
Both germline gene therapy30 and somatic gene therapy3 l
23. See EC LAw, supra note 20, at 428. "The success of the Community depends in
large part on its ability to harmonize Member State laws." Id.
24. Kessler, Regulation, supra note 4, at 1171-72. A protocol is a precise and de-
tailed plan for the study of a biomedical problem or for a regimen of therapy. Id.
25. Theodore Friedmann, Progress Toward Human Gene Therapy, 244 Sci. 1275
(1989) [hereinafter Progress]. "[B]ased on the assumption that definitive treatment for
genetic diseases should be possible by directing treatment to the site of the defect itself
- the mutant gene -" gene therapy is extremely promising scientifically. Id.
26. Human GT, supra note 8, at 809.
27. Progress, supra note 25, at 1275 (supporting proposition that gene therapy is
simultaneously promising and controversial).
28. Judith Areen, Regulating Human Gene Therapy, 88 W. VA. L. REv. 153, 170
(1985) [hereinafter Areen, Regulating Human GT].
29. ARCHER REPORT, supra note 6, at 7.
30. See RECOMBiNANT DNA, supra note 3, at 569 (describing germline gene therapy
as targeting germline cells: gametes, zygotes, and early embryos (4-8 cells)).
31. See id. (describing somatic gene therapy as targeting somatic cells (all other
cells besides germline cells)).
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encompass interventions in which one or more genes32 are intro-
duced within the cells of organisms to treat, diagnose, or prevent
diseases linked to genetic anomalies.3 3 These genetic defects are
the result of a mutation.3 4 A mutation causes the protein de-
rived from such gene either to be absent or to have its activity
altered, affecting the functions of certain or all other cell types
in the body.35 These changes in cellular activity eventually affect
organ functions, generating clinical symptoms that medical doc-
tors may observe.36 The introduction of a functional gene 7 into
a cell 3 may correct cellular imbalances39 resulting from missing
or altered biochemical activity.' The aim of gene therapy,
therefore, is to eliminate the clinical symptoms by attacking
problems at their root.4'
1. Somatic and Germline Gene Therapy Distinguished
Two kinds of gene therapy are generally distinguished:
32. See RECOMBINANT DNA, supra note 3, at 6-7. A gene is a functional unit of
heredity that occupies a specific place or locus on a chromosome, is capable of repro-
ducing itself exactly at each cell division, and is capable of directing the formation of an
enzyme or other protein. Id.
33. ARCHER REPORT, supra note 6, at 1; see STOA, BIOETHICS IN EUROPE 80 (1992)
[hereinafter BIOETHICS IN EUROPE]. "Gene therapy entails inserting a gene, a DNA frag-
ment, into the cells of an organism in order to treat some pathological condition based
on a genetic defect." Id.
34. See RECOMBINANT DNA, supra note 3, at 34. A mutation is a change in the
character of a gene that is perpetuated in subsequent divisions of the cell in which it
occurs. Id.
35. Julie L. Gage, Government Regulation of Human Gene Therapy, 27 JURIMETRICS J.
200 (1987) [hereinafter Gage, Government Regulation].
36. Id.
37. Thomas 0. McGarity & Sidney A. Shapiro, Public Regulation of Recombinant DNA
Gene Therapy, 3J. LEGAL MED. 185, 187-88 (1982) [hereinafter McGarity & Shapiro]; see
RECOMBINANT DNA, supra note 3, at 569 (describing replacement of mutant genes by
normal genes).
38. Progress, supra note 25, at 1276-80. Many techniques, mechanical, physical,
chemical, biological, are used to introduce foreign DNA into the target cells. Id. Inser-
tion techniques include: virus or retrovirus vectors, direct microinjection into the cell
nucleus, electroporation, precipitation by chemical agents, fusion with liposomes, and
shooting with tungsten microprojectiles coated with DNA. Id.
39. Gage, Government Regulation, supra note 35, at 200.
40. Id.
41. BIOETHCS IN EUROPE, supra note 33, at 80. "Recessive mutations can be more
readily treated. ... In this instance, inserting into 'ill' cells a single copy of the normal
gene is enough to restore the function. Recently, the scope of gene therapy has been
expanded from simple correction of mutations to cover treatment of pathological
traits." Id.
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germline and somatic gene therapy.42 The distinction is made
on the basis of the targeted cell type, either germline cells or
somatic cells.4" Germline cells are gametes, 44 zygotes,45 and the
undifferentiated cells of embryos in the early stages of develop-
ment.46 All of these cells have the potential to contribute ge-
netic material to offspring.47 Somatic cells, the remaining cells
of the organism, do not have this potential.48 In somatic gene
therapy the genetic changes introduced are not transmitted to
the progeny, while they would be in the case of germline gene
therapy.49
Because of this potential for the transmission of genetic al-
terations in perpetuity, germline gene therapy is much more
controversial than somatic gene therapy.50 By targeting germi-
42. RECOMBINANT DNA, supra note 3, at 569 (describing distinction drawn between
genetic manipulations involving somatic cells and genetic manipulations involving
germline cells).
43. Id.
44. See Gage, Government Regulation, supra note 35, at 201. Gametes are the sex
cells that contain the genetic information to be transmitted to the offspring. Id. Sper-
matozoa are the male gametes. Id. Ova are the female gametes. Id.
45. See id. Zygotes are fertilized eggs. Id.
46. Id.
47. RECOMBINANT DNA, supra note 3, at 569 (stating that changes resulting from
germline gene therapy would be passed on to subject's progeny).
48. Id. "The outcome [of somatic gene therapy] is a genetic alteration that is re-
stricted to the treated patient .... ." Id.
49. Id. Somatic cell gene therapy eliminates or reduces molecular defects in so-
matic cells, affecting only the individual. Id. Germline gene therapy, however, corrects
genetic defects in germline cells, affecting the individual and its offspring. Id.
50. Id.
Gene therapy involving germ line cells is more controversial, because the mod-
ification is passed on to the children of the treated patient. This is considered
by some to be ethically unacceptable, because, it is argued, we do not have the
right to impose such a change on our descendants, no matter how well inten-
tioned our reasons.
Id.; see Progress, supra note 25, at 1280.
Deliberate or inadvertent modification of human germ line cells can presuma-
bly occur by many of the same methods described here. The potential role of
germ line manipulation for the prevention of genetic disorders is far less clear
than is somatic cell modification, and one response to the possibility of germ
line genetic modification has been to suggest that it is so full of technical and
ethical uncertainties that it should not be performed. However, it seems un-
wise and premature to take such a severe position, and it has been suggested
that the need for efficient disease control or the need to prevent damage early
in development or in inaccessible cells may eventually justify germ line ther-
apy. This most problematical of all issues in gene therapy requires much more
examination.
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nal cells or embryos, germline gene therapy attempts to eradi-
cate the anomaly permanently from the patrimony of future gen-
erations, as well as the individual in the case of embryos.51 Cur-
rently, however, the results of germline gene therapy are highly
unpredictable.52 Although there have been trials in animals,
germline gene therapy has not been performed on humans to
date.5  Thus, it is not yet available in a clinically useful form. 4
Somatic gene therapy, on the other hand, does not involve
changes that affect the patrimony of future generations.5 As a
result, both technically and ethically, somatic gene therapy is not
much different from other high-technology therapeutic inter-
ventions such as organ or bone marrow transplantations.56 As
with other experimental therapeutic techniques, traditional
guidelines must be observed.57 These guidelines include exten-
51. BIoETHiCS IN EUROPE, supra note 33, at 84.
52. Id. at 80. "Current practices involve [both] a high cell lethality (transgenic
animal embryos able to develop normally account for no more than 2-3%) and risks
linked to random insertion of foreign DNA that may give rise to mutations detrimental
to the functionality of the genome." Id.; see Human GT, supra note 8, at 812.
The feeling of many observers is that germline gene therapy should not be
considered until much more is learned from somatic cell gene therapy, until
animal studies demonstrate the safety and reliability of any proposed proce-
dure, and until the public has been educated as to the implications of the
procedure.
Id.
53. RECOMBINANT DNA, supra note 3, at 571 (describing germline gene therapy
experiment in animals); see BIOETHiCS IN EUROPE, supra note 33, at 80. "In animals,
exogenous DNA is usually inserted into 1) gametes 2) in vitro fertilised zygotes (the first
cells obtained by gamete fusion) or 3) into totipotential embryonic cells (cells of em-
bryos at the early developmental stages)." Id.
54. ARCHER REPORT, supra note 6, at 1.
55. RECOMBINANT DNA, supra note 3, at 569.
56. Id. Somatic gene therapy "is analogous to the treatment of genetic disorders
by organ or tissue transplantation." Id.; BIOETHICS IN EUROPE, supra note 33, at 83.
Somatic cell gene therapy is intended as a therapy for genetic diseases by replacing the
defective genetic material at the core of the disease with functioning genetic material.
Id.; Human GT, supra note 8, at 813. Gene therapy procedures currently involve three
basic steps: removal of proliferous cells from the patient; insertion of the desired gene
into in vitro cultured cells; and return of the genetically modified cells back into the
patient. Id.; BIOETHICS IN EUROPE, supra note 33, at 80-81. Such a procedure confines
the applicability of somatic gene therapy to disorders: linked to a recessive genetic trait;
involved with a constitutive expression without implying any complex regulation mech-
anism; affecting proliferous tissues thus allowing in vitro culture of cells (blood cells,
endothelial cells, fibroblasts, hepatic cells); and affecting functions that can be restored
even with a low rate of "corrected" cells. Id.
57. WoRLD MEDICAL ASSOCIATION, DECLARATION OF HELSINKI (revised 1989) [here-
inafter HELSINKI DECLARATION]; GOOD CLINICAL PRACTICE FOR TRlALS ON MEDICINAL
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sive in vitro and animal experimentation"8 and attentive consid-
eration of the costs and risks associated with the transition to
experimentation in humans.59 Currently, somatic gene therapy
is being practiced on human subjects in the context of clinical
trials in a growing number of clinical centers around the world,
including several in European countries.6 °
2. Medical Applications of Gene Therapy
Many genetic disorders are considered treatable through so-
matic gene therapy. 1 Scientists believe that in the future they
will also be able to treat more complex genetic traits and other
kinds of disorders.62 Various approaches, at different stages of
testing, are being investigated to treat cystic fibrosis, atheroscle-
rosis, hemophilia, cancer, and chronic infections such as HIV.6 1
This new technology further allows the rapid tailoring of prod-
ucts for a variety of other applications, including use as vaccines,
diagnostic agents, drug-delivery systems, and treatment of infec-
PRODUCTS IN THE EUROPEAN COMMUNrrY [hereinafter GOOD CLiNicAL PRACTCE] (avail-
able from the Commission of the European Communities); NAT'L COMM'N FOR THE
PROTECTION OF HUMAN SUBJECTs OF BIOMEDICAL AND BEHAVIORAL RESEARCH, BELMONT
REPORT (1975) [hereinafter BELMONT REPORT].
58. Id.
59. Progress, supra note 25, at 1280.
As is true with all other new procedures in medicine, therapeutic studies of
gene therapy in human patients will be performed with imperfect knowledge
when technical uncertainties and imperfections are outweighed by clinical
needs. The balance between uncertain harm and desired benefits has been
examined carefully by a number of religious, ethical, and public policy bodies
.... All have agreed that somatic genetic manipulation for the purpose of
ameliorating disease should be pursued.
Id. (citations omitted).
60. Human GT, supra note 8, at 809.
61. BIOETHICS IN EUROPE, supra note 33, at 81.
Disorders considered treatable through somatic cell gene therapy include: im-
munodeficiency syndrome resulting from adenosine deaminase deficiency
(ADA); immunodeficiency syndrome resulting from a lack of enzyme purino-
nucleoside phosphorylase (PNP); a neurological syndrome resulting from a
deficiency of enzyme hypoxanthine-guanine-phosphoribosyl-transferase
(Lesch-Nyhan); cystic fibrosis (through direct DNA transfer); Duchenne mus-
cular dystrophy; and haemophilia.
Id.
62. Id.; see Ethics, supra note 15, at 225 (stating that as of time article was written in
1986 only simplest kinds of genetic defects were considered viable candidates for gene
therapy).
63. Kessler, Regulation, supra note 4, at 1169-70 (listing diseases being considered
for gene therapy treatment).
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tious diseases.'
After two unsuccessful attempts in the preceding twenty
years,65 a team of researchers from the National Institutes of
Health66 ("NIH") performed the first fully sanctioned and scien-
tifically sound gene therapy intervention in humans in the
United States in 1990.67 An ever-increasing number of clinical
trials have been approved and initiated since, especially in the
United States.68 Progress has been more gradual in Europe
although most Member States have the requisite knowledge and
technology to pursue gene therapy research.69
B. Legal and Ethical Issues Raised by Gene Therapy
As medically promising as gene therapy may be, the pos-
sibilities for abuse inherent in the field are great.70 As an experi-
mental technology, 71 gene therapy also presents risks to its sub-
jects that are not yet fully quantifiable. 72  Thus, gene therapy
raises weighty legal and ethical issues. 73 Within a historical con-
64. Id. (discussing gene therapy products and applications).
65. Fletcher, Moral Problems, supra note 5, at 524-28. Dr. Stanfield Rogers initiated
the first somatic gene therapy trial in humans in 1970. Id. at 525. Rogers attempted
unsuccessfully to treat patients affected by a neurological syndrome caused by a defi-
ciency of the enzyme arginase by using Shope papilloma viruses. Id. This early experi-
ment was followed in 1980 by that of Dr. Martin Cline. Id. at 527. Unlike Rogers, Cline
acted in violation of scientific and ethical research standards for human subjects, at-
tempting gene therapy for thalassaemia through bone marrow treatments. Id. at 527-
28. Both attempts were scientifically premature and generally criticized. Id. at 524-25.
66. See Capron, "Threat", supra note 17, at 671 (describing generally function of
National Institutes of Health ("NIH")). The NIH provides federal support and guide-
lines for gene therapy. Id.
67. BIOETHICS IN EUROPE, supra note 33, at 80. Ultimately, Blaese, Culver, and An-
derson of the National Institutes of Health realized the first authorized gene therapy
initiative in September 1990 in the United States. Id. at 80. The team transferred cells
modified through the insertion of an ADA gene into a patient whose immune system
was seriously endangered. Id.
68. Id.; see Human GT, supra note 8, at 809 (listing protocols initiated in United
States as of May 1992, outnumbering protocols elsewhere around world by ratio of four
to one).
69. Human GT, supra note 8, at 809. In Europe, the first human gene therapy
protocol was initiated by an Italian group based at the Istituto San Raffaele in Milan in
1992. Id. at 811. Various efforts in other Member States of the European Union have
followed. Id. at 809.
70. RECOMBINANT DNA, supra note 3, at 569.
71. BIOETHICS IN EUROPE, supra note 33, at 83.
72. Id.
73. See supra note 14 and accompanying text (discussing the promise and contro-
versy inherent in gene therapy).
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text, gene therapy raises the memory of the racist eugenics and
racial hygiene experiments of Nazi Germany,74 producing fears
of enhancement genetic engineering.7" Within moral and reli-
gious contexts, gene therapy raises concerns for the sanctity of
life.76
Enhancement genetic engineering is closely related to gene
therapy.7 7 It utilizes the same technology and could be carried
out on both somatic and germline cells.78 At present, however,
somatic gene therapy techniques are considered ethically admis-
sible only for the treatment or prevention of serious diseases.79
Should enhancement genetic engineering ever be deemed ad-
missible, a more philosophical debate would have to be initiated
74. DANIEL KEVLES, IN THE NAME OF EUGENICS: GENETICS AND THE USES OF HumAN
HEREDITY (1985) [hereinafter KEVLES, EUGENICS]; BIOTETHIS IN EUROPE, supra note 33,
at 89.
The hottest debate on this issue is probably in Germany where several public
interest associations, organizations of handicapped persons and other groups
have publicly expressed their concern for its potential association with positive
eugenics. This is obviously linked to Germany's history and the connotation
of the word 'eugenics' during the Nazi period. It is very important for the
German public to discuss whether eugenic ideas are favored by the new biol-
ogy and medicine because of Germany's history.
Id.
Generally, European public opinion is favourable towards SGT [somatic gene
therapy] and does not waiver from the attitude of experts. The Eurobarome-
ter 35.1 on Biotechnology shows that the great majority of the persons inter-
viewed think that such research is worthwhile and should be encouraged. The
major opposition to the application of genetic engineering in humans is in
West Germany where 15.2% tend to disagree and 15% definitely disagree with
such applications (9.4% and 10% are the European averages).
Id.
75. Clinical Approach, supra note 3, at 830.
76. Id. at 832.
77. Human GT, supra note 8, at 812. An example of enhancement genetic engi-
neering is the transfer of a gene into cells of a healthy human being with the purpose of
improving desired characteristics such as height. Id.
78. Id.
79. W. French Anderson, Human Gene Therapy: Why Draw a Line?, 14 J. MED. &
PHIL. 681 (1989) [hereinafter Why Draw a Line?]. Serious diseases are diseases that
cause significant suffering and premature death. Id. at 688. Human GT, supra note 8,
at 812 (1992).
Correction of a genetic defect that causes serious illness is one thing, but to try
to alter a characteristic such as size (by administration of a growth hormone
gene to a normal child, for example) is quite another. This area is further
clouded by major social implications as well as by the problem of how to de-
fine when a given gene is being used for treatment (or for preventing disease)
and when it is being used for "enhancement."
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in our society on the ethical implications of betterment of cer-
tain more trivial human traits."0 The current concensus is that
enhancement genetic engineering and its eugenic implications
are inadmissible.81 As sufficient knowledge and expertise to ex-
periment with enhancement genetic engineering exist, 2 how-
ever, thorough control mechanisms must be in place to prevent
any such deviations from legitimate gene therapy procedures.8"
Many observers object to the potential effects of germline
gene therapy, sustaining, on moral"4 or religious"' grounds, the
right of human beings to inherit an unaltered genetic
blueprint.8 6 Germline gene therapy is also controversial because
it involves the manipulation of human embryos.87 Germline
gene therapy, however, could prove to be as promising as so-
matic gene therapy.88 As the development and exploitation of
germline gene therapy is eventually considered or actually per-
mitted, therefore, it will have to be subject to close scrutiny and
tight controls.
80. ARCHER REPORT, supra note 6, at 1-2.
Consequently, enhancement genetic engineering is presently excluded from
the ethically admissible clinical trials and, for that reason, will not be consid-
ered in this Report. If, in the future, clinical and ethical indications arise for
gene therapy of minor diseases or even for certain health improvements, the
matter should be discussed on a case by case basis.
Id.
81. Id.
82. Human GT, supra note 8, at 812.
83. Ethics, supra note 15, at 225.
84. EdwardJ. Larson, Human Gene Therapy and the Law: An Introduction to the Litera-
ture, 39 EMORY LJ. 855, 861-62 (1990) [hereinafter Larson, Introduction]; see Fletcher,
Moral Problems, supra note 5, at 515 (discussing generally and defining moral and ethical
issues).
85. See Clinical Approach, supra note 3, at 832-36 (discussing societal, personal, and
religious issues surrounding germline gene therapy, including sanctity of life).
86. BIOETHIcS IN EUROPE, supra note 33, at 84.
Many authors sustain that man - including future generations - is entitled to
certain rights including the right to inherit a non-modified patrimony and the
right of autonomy. Consequently, man should respect the patrimony and au-
tonomy of future generations. For this reason alone some would like to see
[germline gene therapy] prohibited. Others sustain that the human genome
is sacred and therefore intangible calling for the ban of this technique.
Id.; see RECOMBINANT DNA, supra note 3, at 569 (presenting argument that changes may
not be imposed on future generations).
87. ARCHER REPORT, supra note 6, at 10.
88. Progress, supra note 25, at 1280.
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C. Current Regulatory Frameworks in the European Union
Efforts at gene therapy regulation in the European Union
have resulted in different approaches for germline gene therapy
and somatic gene therapy.89 While the former generally is cur-
rently considered to be too risky,90 the latter is less controversial
and in some ways akin to other high-technology therapies.9
Certain aspects of somatic gene therapy, therefore, are subject
either to broader existing EU biotechnology regulations9" or to
the controls of the European Medicines Evaluation Agency.93
To date, however, gene therapy guidelines exist only at various
levels within the individual Member States.9" No comprehensive
Union-wide regulation of gene therapy research has been articu-
lated.95
89. See BIOETHIcs IN EUROPE, supra note 33, at 80-91 (discussing different treat-
ment of each type of gene therapy).
90. Human GT, supra note 8, at 812.
91. Id.; see BIOETHIcs IN EUROPE, supra note 33, at 87.
The Danish Council of Ethics, in its 1989 report on the protection of human
gametes, fertilized ova, embryos and fetuses, stated that gene therapy does not
in principle differ from other forms of highly specialized treatment if it can be
established that the genetic material is not unintentionally transferred to germ
line cells.
Id. Both the French National Advisory Committee on Ethics and the Italian Comitato
Nazionale per la Bioetica compare somatic gene therapy to other technically advanced
and experimental treatments. Id.
92. Commission of the European Communities, Communication: Biotechnology and
the White Paper on Growth, Competitiveness and Employment: Pr6paring the Next Stage at 4-5
(1994) [hereinafter Commission Communication], in COMMISSION OF THE EUROPEAN COM-
MUNITIES, ETHICS AND BIOTECHNOLOGY. INFORMATION DOSSIER ON THE GROUP OF ADVIS-
ERS ON ETHICAL IMPLICATIONS OF BIOTECHNOLOGY 26-27 (May 1994) [hereinafter COM-
MISSION DOSSIER].
93. Commission of the European Communities, Activities of the European Commission
in the Field of Bioethics at 6-7 (1994) [hereinafter Commission Activities], in COMMISSION
DOSSIER, supra note 92, at 50-51.
94. ARCHER REPORT, supra note 6, at 7-8.
95. Ethics, supra note 15, at 226. By comparison, all protocols in the United States
are subject to the regulations of the National Institutes of Health's Recombinant DNA
Advisory Committee ("RAC") and the Food and Drug Administration ("FDA"), which
have been responsible for developing a regulatory framework and technical standards
for academic and commercial gene therapy researchers. Id. The guidelines of RAC
and the FDA have provided researchers, scientific institutions, and pharmaceutical
companies in the United States with uniform, comprehensive parameters within which
to operate. Id. The United States continues to lead in the field, devoting extensive
resources to gene therapy. Id. Thus, gene therapy research and product development
are progressing rapidly. Id.
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1. Germline Gene Therapy
Germline gene therapy research in Europe, as elsewhere, is
currently limited to trials that do not involve human subjects,
such as the creation of transgenic animals.9 6 Although germline
gene therapy may prove to be the only means of treating certain
diseases,97 most experts agree that the application of germline
gene therapy in humans is too dangerous given the present state
of knowledge.98 In fact, the European Parliament issued a reso-
lution in 19899 formally prohibiting experiments aimed at mod-
ifying the human genetic blueprint,100 providing for criminal
prosecution of gene transferral into human gametes, 1 1 and stat-
ing that each modification of the human genome represents an
unacceptable and unjustifiable distortion of the human iden-
tity.1
0 2
2. Somatic Gene Therapy
Consensus on the desirability of somatic gene therapy is
greater than for germline gene therapy.10 3 Because prospects
for agreement on many aspects of somatic gene therapy are not
evident among the Member States,' no attempts to articulate
comprehensive, Union-wide regulations have been made. 05
The Member States, therefore, have undertaken gene therapy
regulation independently.10 6
96. BIOETHICS IN EUROPE, supra note 33, at 89.
97. ARCHER REPORT, supra note 6, at 11. At its 1990 Conference, the Council for
International Organizations of Medical Sciences declared that continued discussion of
germline gene therapy was essential, as the modification of human germ cells for thera-
peutic or preventive purposes not presently in prospect might be the only means of
treating certain conditions. Id.
98. See supra notes 49-53 and accompanying text (discussing serious implications
of germline gene therapy experiments given power to alter genetic blueprint of future
generations).
99. Parliament Resolution on Ethical and Legal Problems of Genetic Manipula-
tions A2-327/88 (1988).
100. Id.
101. Id.
102. Id.
103. Id. The Resolution stated that somatic gene therapy should be supported and
a list of diseases treatable through gene therapy created. Id.
104. Human GT, supra note 8, at 812.
105. BIOETHICS IN EUROPE, supra note 33, at 87.
106. Id. at 86-88.
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a. Disparate National Efforts
The task of establishing guidelines for somatic gene therapy
has been left to numerous local and national bodies, °7 includ-
ing ethics committees, 0 1 scientific institutions, public interest
groups,'0 9 and governmental agencies."0 Having studied the
implications and applications of somatic gene therapy, these
bodies have articulated various sets of conditions to be met and
precautions to be taken when conducting research in the
field."' Although some common general elements may be
found in most of these sets of recommendations," 2 they usually
differ in other ways." 3
In Italy, where the first European clinical trial of somatic
gene therapy in humans was performed," 4 the Minister of
Health established the Commission of Inquiry on Genetic Engi-
neering in 1985.115 This commission's final report offered a pos-
itive opinion of somatic gene therapy.116 In February 1991, the
Comitato Nazionale per la Bioetica" 7 ("Comitato") published a
report favorable to somatic gene therapy." 8 In this report, the
Comitato equated somatic gene therapy with other experimen-
107. Id. at 86-87.
108. Id. Examples of such committees are the Comitato Nazionale per la Bioetica
[National Committee for Bioethics] in Italy and the Comit6 Consultatif National
d'Ethique [National Advisory Committee on Ethics] in France. Id. at 87. In the United
Kingdom, the Department of Health established the Special Committee on the Ethics
of Gene Therapy in 1989. Id. Chaired by Sir Cecil Clothier, the Committee issued a
report ("Clothier Report") in favor of somatic gene therapy in January of 1992. Id.
109. Id. For example, the Genetic Interest Group ("GIG"), a public interest group
in the United Kingdom, has published a position paper supporting the use of somatic
gene therapy for the treatment of human genetic disorders. Id.
110. Thomas Tursz, Protocole de transfert d'un gbne marqueur par un adinovirus recombi-
nant dfetif administrpar voie intra-tumorale directe sous contr6lefibroscopique dans les cancers
broncho-pulmonaires humains [Protocol for the Transfer of a Reporter Gene by Recombination
Defective Adenovirus Administered by Direct Intratumoral Means Under Fibroscopic Control in
Human Broncho-Pulmonay Cancers] (1993) [hereinafter Tursz Protocol]. In France, for
example, the Ministry of Higher Education and Research and the Ministry of Health
both oversee gene therapy research. Id. at 53.
111. BIOETHICS IN EUROPE, supra note 33, at 86-87.
112. See supra note 57 and accompanying text (discussing widely-recognized gen-
eral guidelines for clinical research).
113. ARCHER REPORT, supra note 6, at 7-8.
114. Human GT, supra note 8, at 811.
115. BIOETHICS IN EUROPE, supra note 33, at 87.
116. Id.
117. Id. [National Committee for Bioethics].
118. Id.
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tal, high-technology therapies, finding trials in human subjects
permissible. 9 The Comitato also recommended that a national
authority overlook somatic gene therapy.12 This national au-
thority would be responsible for updating the list of diseases for
which somatic gene therapy treatment is allowed, developing
guidelines for somatic gene therapy research, and monitoring
the results of ongoing trials.' 21
In Germany, the Bundestag Commission of Inquiry on Ge-
netic Engineering ("BCI") concluded in its final report, in 1987,
that somatic gene therapy was justifiable and similar to the trans-
fer of living material.' 22 The BCI, however, encouraged the
practice of providing somatic gene therapy patients with addi-
tional medical advice from an independent physician.' 2  The
BCI also requested that a clear definition of the medical indica-
tions of somatic gene therapy be articulated in co-operation with
the Ethics Commission of the Federal Chamber of Physicians.1 24
In 1989, the Federal Chamber of Physicians published guide-
lines for somatic gene therapy protocols. 25 In addition, local
institutional review boards and ethics committees must approve
somatic gene therapy trials.'12
In France, the Comit Consultatif National d'Ethique127
("CCNE") published an opinion on somatic gene therapy in De-
cember 1990.128 The CCNE raised no objections to somatic
gene therapy in the opinion.129 The CCNE recommended, how-
ever, that somatic gene therapy be restricted to serious heredi-
tary diseases.' 0 In 1993, the CCNE recommended that somatic
gene therapy be governed by Law No. 88-1138's' ("Loi Huriet")
119. Id.
120. Id. at 88.
121. Id.
122. Id. at 87.
123. Id. at 88.
124. Id.
125. Id. The Federal Chamber of Physicians found that several diseases did not
meet the requisite genetic criteria, excluding these diseases from its list of diseases for
which somatic gene therapy treatment is permissible. Id.
126. ARCHER REPORT, supra note 6, at 8.
127. BIOETHIc S IN EUROPE, supra note 33, at 88 [National Advisory Committee on
Ethics].
128. Id.
129. Id. at 87.
130. Id. at 88.
131. Loi No. 88-1138 du 20 d~cembre 1988, J.O., Dec. 22, 1988, at 16,032 (relative
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on biomedical experimentation on human beings.13 2 Thus, so-
matic gene therapy protocols must be evaluated by the local re-
search ethics committees in addition to other national bodies.13 3
b. Applicable EU Directives
Because somatic gene therapy is not considerably different
from other technologically advanced therapies,1 3 4 certain of its
elements, such as the viral vectors1 35 used in some instances,1 3 6
are governed by preexisting broader biotechnology regula-
tions,1 3 7 such as Council Directives 90/219 on the contained use
of genetically modified organisms l3 ' and 90/220 on the deliber-
ate release into the environment of genetically modified orga-
nisms."3 9 Since the Directives' entry into force on October 23,
1991,140 Member States have adopted or are in the process of
adopting the necessary implementing legislation.14' Countries
with more vigorous biotechnology sectors are reporting releases
in accordance with Council Directive 90/220.142
i la protection der personnes qui se pr8tent ! des recherches biom~dicales [relating to
the protection of persons lending themselves to biomedical research]).
132. ARCHER REPORT, supra note 6, at 7.
133. Id.; see Tursz Protocol, supra note 110. In this protocol for a somatic gene ther-
apy trial for human broncho-pulmonary cancer performed in France in the summer of
1994, Professor Tursz included copies of the correspondence with and authorizations
from the various advisory committees for the protection of individuals. Id. at 53-64. As
for all trials in France, Professor Tursz's protocol had to receive the approval of the
CCNE, la Commission du Cnie Gnkique du Ministre de l'Enseignement Sup~rieur
et de la Recherche [Commission on Genetic Engineering of the Ministry of Higher
Education and Research), la Commission du GCnie Biomolpculaire du Ministate de
l'Agriculture et de la Poche [Commision on Biomolecular Engineering of the Ministry
of Agriculture and Fishing], and le Groupe d'Experts sur la Suret6 Virale des M~dica-
ments du Ministore de la Santh [Group of Experts on the Viral Safety of Medicines of
the Ministry of Health]. Id. at 54-62. In addition, the approval of the specific local
committee was also required, in this case le Comit6 Consultatif de Protection des Per-
sonnes clans la Recherche Biom~dicale de Bictre [Advisory Committee on the Protec-
tion of People in Biomedical Research of the municipality of Bic~tre]. Id. at 63-64.
134. BIOETHICS IN EUROPE, supra note 33, at 85.
135. See supra note 38 (disussing gene insertion techniques).
136. Id.
137. Commission Communication, supra note 92, at 4-5, in COMMISSION DOSSIER,
supra note 92, at 26-27.
138. Council Directive No. 90/219, O.J. L 117/1 (1990).
139. Council Directive No. 90/220, O.J. L 117/15 (1990).
140. Commission Communication, supra note 92, at 15-17, in COMMISSION DOSSIER,
supra note 92, at 37-39.
141. Id,
142. Id.
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c. The European Medicines Evaluation Agency
Besides such general biotechnology guidelines, certain
other aspects of somatic gene therapy will come under the con-
trol of the European Medecines Evaluation Agency ("EMEA"),
which is designed to enforce centralized, Union-wide marketing
authorization procedures for medicinal biotechnology prod-
ucts. 4 Created under Council Directive 93/41,'" the EMEA
began operating on January 1, 1995.145 The EMEA's Manage-
ment Board is made up of representatives of the Member States,
the European Commission, and the European Parliament."4 Fi-
nal recommendations by the EMEA's staff are approved and put
into law by the Commission of the European Communities
("Commission") 147
The ultimate goal of the EMEA is to streamline existing
marketing authorization procedures so that patients can benefit
from innovative medicinal products simultaneously in all Mem-
ber States, while at the same time safeguarding maximum stan-
dards of public health.'4 To this end, beginning in 1995, the
EMEA will impose three registration procedures for medicines
in the Union: a centralized EU procedure valid for the fifteen
Member States and restricted to certain new medicines; 49 a de-
centralized procedure, applying to most medicines, based on
mutual recognition of national authorizations; 150 and a national
procedure for certain medicines restricted to the market of a
single Member State.' 5 '
II. ANALYSIS OF THE LATEST DEVELOPMENTS
Both the United States and Japan, Europe's primary com-
petitors in biotechnology and genetic research and applications,
143. Id. at 6-7, at 28-29; Commission Acivities, supra note 93, at 6-7, in COMMISSION
DOSSIER, supra note 92, at 50-51.
144. Council Directive No. 93/41, O.J. L 214/40 (1993).
145. Id.
146. Commission Activities, supra note 93, at 7, in COMMISSION DOSSIER, supra note
92, at 51.
147. Id.
148. Commission Communication, supra note 92, at 6, in COMMISSION DOSSIER, supra
note 92, at 28.
149. Commission Activities, supra note 93, at 6, in COMMISSION DOSSIER, supra note
92, at 50.
150. Id.
151. I&
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have established uniform guidelines for gene therapy.152 The
Member States of the European Union, in comparison, have not
followed a uniform approach to somatic gene therapy regula-
tion. 153 Determined.to remain competitive and to maximize the
potential of its infrastructure, the Union decided to reexamine
its biotechnology framework."M As a result, the European Com-
mission issued Growth, Competitiveness and Employment: The Chal-
lenges and Ways Forward Into the 21st Centuiy, White Paper155 (" White
Paper"), in 1993, offering an ambitious agenda of harmonization
and coordination of research efforts and regulations. 156 The
proposals were intended to help the Union realize the full medi-
cal and economic promise of gene therapy, ensuring its status as
a producer and not simply a consumer of biotechnology prod-
ucts.15 7 Former Commission President Jacques Delors also pro-
posed the creation of the Group of Advisers on the Ethical Impli-
cations of Biotechnology. 15 8 In December 1994, one of its mem-
bers, Professor Luis Archer of Portugal, presented a Report on
Ethical Aspects of Gene Therapy'59 ("Archer Report"), destined to in-
form and guide the Commission and the European Parliament
("Parliament") in assessing gene therapy.1 6°
A. Harmonization in the European Union
Harmonization of Member State laws is necessary for the
EU to be successful. 161 Under Article 36 of the EC Treaty, how-
ever, Member States are allowed to articulate and retain national
regulations.' 62 These national regulations often become impedi-
152. See supra note 95 and accompanying text (discussing regulatory framework in
United States); David Swinbanks, Gene Therapy Gets Double Dose of Screening, 367 NATURE
399 (1994) (discussing regulation of human applications of gene therapy by central
government agencies in Japan).
153. ARCHER REPORT, supra note 6, at 7-8.
154. White Paper, supra note 21.
155. Id.
156. Id.
157. Id.
158. Commission of the European Communities, European Commission's Group of
Advisers on the Ethical Implications of Biotechnology, Activity Report 1991-93 at 6 (1993)
[hereinafter Advisers'Activity Report], in COMMISSION DOSSIER, supra note 92, at 83.
159. ARCHER REPORT, supranote 6.
160. Id.
161. EC LAw, supra note 20, at 428.
162. EC Treaty, supra note 18, art. 36.
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ments to trade and technological advancements. 163 Thus, Arti-
cle 100 authorizes the Council of Ministers ("Council") to adopt
harmonization measures in the form of directives by a unani-
mous vote.164 Article 100a facilitates the adoption of harmoniza-
tion measures and supplements Article 100, authorizing the
Council to adopt harmonization legislation in the form of either
directives or regulations by a qualified vote. 6 ' Article 100a also
involves the Parliament in the legislative process. 166
In the face of increasing barriers due to regulation of rapid
technological advances at the Member State level, 167 however,
the Commission adopted a "new approach" to technical harmo-
nization in 1985.168 The "new approach" restricts harmonization
of laws to the adoption of essential safety requirements in the
form of voluntary technical standards drawn up by relevant in-
dustrial standardization bodies.169  Since the Commission
adopted the "new approach," fewer directives have been
adopted. 7 ° Taking the form of "frameworks," those directives
that have been adopted set critical minimum health, safety, and
technical requirements, with details to be supplied by the Com-
munity standards bodies.' 7 '
B. The White Paper
In 1993, in response to the economic situation of the Mern-
ber States in a changing environment, 172 and particularly in re-
163. EC LAw, supra note 20, at 428. "Technical barriers also retard technological
advance, since they divert capital from basic research to secondary development costs
.... Id.
164. Id. at 428-31.
165. EC Treaty, supra note 18, arts. 100-100a; see EC LAw, supra note 20, at 439-40.
"Directives require implementing Member State laws or regulations within the time pe-
riod specified (usually two years)." Id. at 430. Regulations have immediate force of law
throughout the European Union. Id.
166. EC LAw, supra note 20, at 439-40.
167. Id. at 442.
168. Id. at 443.
169. Id. at 445.
170. Id.
171. Id. For example, a directive for active implantable medical devices was
adopted under the "new approach." Id.
172. White Paper, supra note 21, COM (93) 700 Final, at 2. The White Paper stated
that over the last 20 years: the European economy's potential rate of growth has
shrunk, from around 4% to around 2.5% a year; unemployment in the Union has been
steadily rising from cycle to cycle; the investment ratio has fallen by five percentage
points; and the competitive position of the Union in relation to the United States and
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sponse to unemployment,173 the Commission issued the White
Paper.174 In the White Paper, the Commission proposed solutions
to some of these economic problems, identifiying promising ar-
eas, such as biotechnology, in which the Union could capitalize
on its strengths.' 75 Thus, the White Paper was a call to action for
the Union to remain competitive globally, acknowledging that
the Member States needed to make a concerted effort to maxi-
mize their common potential. 176
In the White Paper, the Commission recognized the need for
well-considered regulation in the area of biotechnology, striking
the proper balance between the advancement of research and
the management of risks.171 It also offered three major recom-
mendations concerning biotechnology.1 78  First, the Union
should be willing to review its regulatory framework, given the
importance of regulations to research and industry efforts.179
Japan has worsened in the areas of employment, export market shares, research and
development and its incorporation into market goods, and the development of new
products. Id.
173. Id.
174. Id.
175. Id. at 116, 5.7.
The sectors with the greatest potential for the applications of biotechnol-
ogy are amongst the most vigorous and competitive sectors in the Community
with a long record of sustained growth, productivity increase, and highly com-
petitive trade performance.
The Community firms in these sectors (chemicals, pharmaceuticals, agri-
cultural processing) are leading firms at a global level with important capabili-
ties in the domain of innovation.
Among other factors favouring investment in biotechnology in the Com-
munity are the strong science base and infrastructure, the availability of skilled
labour, and the high quality of process engineering and production facilities.
Id.
176. Id. at 5. "We are thus setting out a number of broad guidelines which have a
predominantly economic basis, although it will be seen that they cannot be dissociated
from the major trends which are affecting society itself: an economy that is healthy,
open, decentralized, competitive and based on solidarity." Id.
177. Id. at 117, 5.8.
Regulation concerning the safety of applications of the new biotechnology is
necessary to ensure harmonization, safety, and public acceptance. However,
the current horizontal approach is unfavourably perceived by scientists and
industry as introducing constraints on basic and applied research and its diffu-
sion and hence having unfavourable effects on EC competitiveness.
Id.
178. Id.
179. Id. at 118, 1 5.9.
Given the importance of regulations for a stable and predictable environment
for industry and given that they influence localization factors such as field
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Second, the Union must work to reinforce scientific support for
regulations. 18° Third, the Union ought to focus on the most vig-
orous biotechnology research and development domains and to
increase coordination of research efforts.1 8 ' Given these recom-
mendations, the Commission made clear that regulation and
harmonization18 2 are at the core of remaining competitive in
biotechnology."' 3
By stressing the outstanding potential of biotechnology for
innovation and prosperity, the White Paper's recommendations
were an' impetus in mobilizing people and organizing efforts for
the articulation and harmonization of Union policy toward the
trials and scientific experimentation, the Community should be open to re-
view its regulatory framework with a view to ensuring that advances in scien-
tific knowledge are constantly taken into account and that regulatory oversight
is based on potential risks. A greater recourse, where appropriate, to mutual
recognition, is warranted to stimulate research activities across Member States.
Furthermore, if the Community is to avoid becoming simply a market rather
than a producer of biotechnology-derived products then it is vital that Com-
munity regulations are harmonized with international practice. The develop-
ment of standards will supplement regulatory efforts.
Id.
180. Id.
The Commission intends to make full use of the possibilities which exist in the
present regulatory framework on flexibility and simplification of procedures as
well as for technical adaptation. To sustain a high level of environmental pro-
tection and to underpin public acceptance, it is importait to reinforce and
pool the scientific support for regulations. An advisory scientific body at Com-
munity level for biotechnology diffusion drawing on the scientific expertise
within and at the disposal of the existing committees at national and Commu-
nity level . . . could play a crucial role in intensifying scientific collaboration
and in providing the needed support for a harmonized approach of the devel-
opment of risk assessments underlying product approval. This body could also
advise on the development of a further Community strategy for biotechnology.
Id.
181. Id.
Since the Community is not matching efforts elsewhere in research and devel-
opment expenditure, it needs to compensate for this through focusing on the
most vigorous biotechnology research and development domains and in-
creased coordination between the Community and Member States in order to
avoid duplication, encourage collaborative research and improve efficiency of
expenditure on research and developement.
Id.
182. Supra notes 161-71 and accompanying text (discussing benefits of harmoniza-
tion).
183. See supra note 179 and accompanying text (discussing efforts Union must
make to remain competitive).
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field.1 84 In a subsequent communication, however, the Commis-
sion, after highlighting some of the recommendations of the
White Paper, proposed postponing any major decisions until
1997.185 The Commission stated that a review of the regulatory
framework would be warranted in light of new developments. 86
C. The Group of Advisers
Recognizing that neither the Commission nor the Parlia-
ment possessed the requisite knowledge to make informed deci-
sions affecting high technology fields, 8 7 and on the basis of a
proposal by then Commission President Jacques Delors, the
Commission created the Group of Advisers on the Ethical Impli-
cations of Biotechnology ("Group of Advisers") on November
20, 1991.188 The Group of Advisers is designed to report to the
Commission on scientific matters that either the Commission or
the Group on its own initiative decides to investigate.189 The
184. Commission Communication, supra note 92, at 1, in COMMISSION DOSSIER, supra
note 92, at 23.
185. Id. at 7, in COMMISSION DOSSIER, supra note 92, at 29.
186. Id.
187. PresidentJacques Delors & No~lle Lenoir, Press Conference, Brussels, 24 May
1994 [hereinafter Press Conference], in COMMISSION DOSSIER, supra note 92, at 12.
Ni la Commission, nile Parlement europ~en, nile Conseil ne peuvent trouver
dans leurs connaissances les 6l6ments suffisants pour trancher certains
probl~mes fondamentaux; et pourtant, ils sont obliges A prendre des d~ci-
sions. C'est pourquoi ils demandent l'avis de personnes particulirement com-
p&entes et totalement ind~pendantes, qui ne re~oivent aucune instruction
.... [I] l est absolument indispensable que les d~cideurs disposent d'6lments
qui leur permettent de dcider et d'informer objectivement l'opinion pub-
lique, en dehors des pressions des lobbies et d'une certaine presse.
1d. [Neither the Commission, the European Paliament, nor the Council can find in
their knowledge the necessary elements to decide certain fundamental problems; and
yet, they are forced to make these decisions. Such is the reason why they seek the
advice of particularly competent and totally independant persons who receive no in-
structions .... [I]t is absolutely indispensible for the decision-makers to have access to
elements which permit them to decide and to inform the public opinion objectively,
outside the pressures of lobbies and a certain press.] (translation by Note Author).
188. Commission Activities, supra note 93, at 1, in COMMISSION DOSSIER, supra note
92, at 45. "The Group of Advisers was set up in November 1991 following the Commis-
sion's communication entitled 'Promoting the Competitive Environment for Industrial
Activities Based on Biotechnology Within the Community.'" Id.; see Advisers' Activity
Report, supra note 158, at 6, in COMMISSION DOSSIER, supra note 92, at 83 (discussing
Group of Advisers' creation and role).
189. Press Conference, supra note 187, at 1, in COMMISSION DOSSIER, supra note 92,
at 12. "Mme Lenoir a insist6 sur le caract~re libre et ind~pendant des travaux du
groupe, qui peut entreprendre l'&ude d'un probl~me aussi bien de son initiative qu't
la demande de la Commission." Id. ["Mrs. Lenoir insisted on the free and in-
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Group is intended to remain partly autonomous, distinguishing
it as an objective source of information for policy makers.1 90
Now in its second term,' 9' the Group has nine members. 192 One
of them, Professor Luis Archer, a geneticist from Portugal, was
asked to report on gene therapy. 93 Professor Archer's findings
are intended to guide the Commission as it considers pertinent
regulations in the future.'94
dependant character of the work of the group, which can undertake the study of a
problem of its own initiative just as well as at the Commission's request."] (translation
by Note Author).
190. Id.
191. Commission Activities, supra note 93, at 1, in COMMISSION DOSSIER, supra note
92, at 45.
The Group of Advisers issued three opinions during its first term (1991-93).
The first was on BST (bovine somatotropin), the second was on the legal pro-
tection of biotechnological inventions and the third on products derived from
human blood or human plasma. The group is currently looking at the ethical
implications of gene therapy, the use of transgenic animals and prenatal diag-
nosis.
Id.
192. Advisers' Activity Report, supra note 158, at 6, in COMMISSION DOSSIER, supra
note 92, at 83. "In view of the nature of the interests at stake a pluralist and mul-
tidiciplinary approach was called for. The members of the Group of Advisers are ac-
cordingly drawn from the worlds of science, law, philosophy.and politics. Each member
serves a two-year term." Id.; see Commission of the European Communities, Composition
of the Group of Advisers on Ethical Implications of Biotechnology (1993) [hereinafter Composi-
tion], in COMMISSION DOSSIER, supra note 92, at 73-76. The members of the Group of
Advisers are: Mrs. No~lle Lenoir, a French politician and President of the Group of
Advisers; Prof. Luis Archer, a Portuguese scientist; Prof. Gilbert Hottois, a Belgian phi-
losophy professor; Dr. Anne McLaren, a British scientist; Prof. Dietmar Mieth, a Ger-
man theology professor; Dr. Margareta Mikkelsen, a Danish physician; Dr. Octavi
Quintana Trias, a Spanish physician; Prof. Stefano Rodota, an Italian law professor; and
Prof. Egbert Schroten, a Dutch theology professor. Id.
193. Advisers' Activity Report, supra note 158, at 7, in COMMISSION DOSSIER, supra
note 92, at 84.
One member is appointed rapporteur for each topic selected, depending on
his or her expertise and interests. Once the research is completeted, the rap-
porteur drafts a report accompanied by a draft opinion, which is then consid-
ered by the Group. Dissenting opinions may also be attached.
Id.; see id. at 11-12, at 88-89 (discussing Group of Advisers' works in progress).
194. Press Conference, supra note 187, at 1, in COMMISSION DOSSIER, supra note 92, at
12. "Le groupe va franchir a present une nouvelle 6tape. Grice aux moyens accrus
dont il disposera, il pourra notarnment: . . . aborder aussi des 'sujets d'anticipation'
comme la m~decine g~n~tique.. . ." Id. ["The group will presently reach a new stage.
Due to the increased means at its disposal, it will be able to: ... investigate also upcom-
ing subjects such gene therapy.... ."] (translation by Note Author); see Advisers'Activity
Report, supra note 158, at 7, in COMMISSION DOSSIER, supra note 92, at 84. "The Group's
opinions are purely advisory. They are designed to guide the Commission in biotech-
nology-related activities to enable it to lay down ethically responsible rules." Id.
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D. The Archer Report
On September 23, 1993, the Commission requested an eval-
uation of gene therapy from the Group of Advisers. 195 In re-
sponse to the Commission's request, Professor Archer presented
a Report on Ethical Aspects of Gene Therapy ("Archer Report") on De-
cember 13, 1994.196 The Archer Report consists of four parts: 1)
Definitions; 197 2) Ethical Evaluation of Somatic Gene Ther-
apy;' 98 3) Ethical Review of Somatic Gene Therapy Protocols and
Products;1  and 4) Ethical Evaluation of Germline Gene Ther-
apy.200
1. Definitions
The first part of the Archer Report reviewed briefly some of
the background scientific information.' It defined gene ther-
apy and distinguished between somatic and germline gene ther-
apy, outlining the implications of each.202 The Archer Report also
stated that it would not cover enhancement genetic engineer-ing. 20
2. Ethical Evaluation of Somatic Gene Therapy
The second part of the Archer Report began by stressing that
2041 ucgene therapy remained in its experimental stages. As such,
somatic gene therapy trials should currently be subjected to the
widely-recognized ethical principles for experimental therapies
195. Advisers' Activity Report, supra note 158, at 12, in COMMISSION DOSSIER, supra
note 92, at 89.
196. ARCHER REPORT, supra note 6.
197. Id. at 1.
198. Id. at 3
199. Id. at 7.
200. Id. at 10.
201. Id. at 1.
202. Id.
203. Id. at 2.
At present, somatic gene therapy techniques are considered ethically admissi-
ble only for the treatment or prevention of serious diseases... the latter being
defined as diseases which cause significant suffering and premature death....
Consequently, enhancement genetic engineering is presently excluded from
the ethically admissible clinical trials and, for that reason, will not be consid-
ered in this Report.
204. Id. at 3.
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of the Helsinki Declaration °5 and the Belmont Report.20 6 The
Archer Report summarized these priciples in four broad points
along which it structured its discussion: benefits for the patient
should be expected;2 0 7 disproportionate risks should be ex-
cluded;218 the dignity and autonomy of the person should be
respected;2 0 9 and justice should be attained. 210
a. Benefits
In considering the benefits to be derived from somatic gene
therapy, the Archer Report highlighted the promise somatic gene
therapy holds in alleviating, curing, or preventing both genetic
and acquired diseases.21 1 The Archer Report emphasized the
promise somatic gene therapy holds in the fight against diseases
for which there are only poor or no alternative therapies.21 2 Pro-
fessor Archer also stressed the profound impact it will have on
medicine, especially as the use of in vivo techniques facilitating
and broadening the administration of gene therapy increases.213
205. HELSINKI DECLARATION, supra note 57; see supra note 57 and accompanying
text (discussing widely-recognized general guidelines of Helsinki Declaration).
206. BELMONT REPORT, supra note 57.
207. ARCHER REPORT, supra note 6, at 3.
208. Id.
209. Id.
210. Id.
211. Id.
212. Id. at 3-4.
In addition to the adenosine deaminase (ADA) deficiency, other genetic dis-
eases have been the object of gene therapy protocols, namely familial
hypercholesterolemia, cystic fibrosis, Gaucher disease, glucocerebrosidase and
hemophilia B. Acquired diseases like AIDS, cardiovascular diseases, and can-
cer are also being contemplated by gene therapy. As a matter of fact, cancer is
the disease for which about two thirds of gene therapy protocols have been
designed.
Id.
213. Id. at 3.
Initially, somatic gene therapy was always performed ex vivo. This means that
target cells were removed from the patient, grown in culture in vitro, geneti-
cally modified by the use of an appropriate vector, and then harvested and
finally reimplanted in the same patient. More recently, an in vivo strategy
started being developed which involves direct administration of the gene-car-
rying vector into the patient's organism. As this latter strategy tends to be
used more progressively, each of the individual clinical trials will be less de-
pendent on sophisticated high-technology, and the ethical use of somatic gene
therapy will become much easier and more widespread. It will then have a
profound impact on medicine.
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b. Risks
In assessing the risks of somatic gene therapy, the Archer Re-
port raised two considerations. 214 The first is that risks are pres-
ent in all aspects of somatic gene therapy, given its experimental
nature.215 Secondly, the risks could not be fully quantified until
greater knowledge was accumulated, especially as to secondary
side effects.216
The Archer Report highlighted the need to strike a balance
between permissiveness and control in regulating somatic gene
therapy.217 This balance is important to ensure that the benefits
of somatic gene therapy may continue to be available without
serious incidents threatening the entire endeavor. 218 The Archer
Report stated that most existing regulations recognize the need to
proceed cautiously in light of the risks.2 19 Most of these regula-
tions, therefore, prescribe that the diseases initially selected for
gene therapy should be serious, and lack effective alternative
treatments. 2 0 Only after such trials have proven safe and effec-
tive should researchers and physicians contemplate treatment of
214. Id. at 4-5.
215. Id. at 4.
216. Id.
In order to evaluate risks, sufficient scientific knowledge on the physi-
opathology of the disease and on the molecular biology of the gene con-
cerned, as well as its vector, are required. This knowledge, together with
animal experimentation (including that [on] non-human primates), should
show whether or not (i) the therapeutic gene is expected to be inserted at the
right place in the target cells and to remain there long enough to be effective,
(ii) the introduced gene is appropriately regulated, producing acceptable
amounts of the product and (iii) there are no secondary effects. This latter
requirement is, presently, very difficult to assess.
Id.
217. Id.
218. Id.
It is important that the public is aware of these potential risks, so that the
review and oversight of gene therapy protocols do not become too relaxed
and when the first serious problems come, the public does not force a halt or
significant slowdown of gene therapy research, which should, nevertheless,
continue and be encouraged to the benefit of so many patients.
Id.
219. Id. at 4.
220. Id.; see id. n.2 (referring specifically to documents from France and United
Kingdom); Gene Therapy in Man: Recommendations of European Medical Research Councils, 1
LANCET, 1271, 1271 (1988) [hereinafter Recommendations of Councils]. The guidelines of
the European Medical Research Council mention "diseases which are invariably fatal or
severely disabling and for which current therapies ... are not always feasible or carry a
high level of risk." Id.
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less burdensome diseases for which alternative treatments ex-
ist.221
c. Dignity and Autonomy
The Archer Report reiterated the conventional need to re-
spect the dignity, health, and privacy of patients undergoing so-
matic gene therapy.2 It also emphasized the importance of in-
formed consent and full disclosure to the patient.223  Once
again, however, the experimental nature of somatic gene ther-
apy was such that the Archer Report was compelled to articulate a
standard of disclosure to patients higher than that for conven-
tional treatments. 224
d. Justice
The Archer Report addressed the need to select patients and
the diseases to be treated by somatic gene therapy fairly. 22 5 So-
matic gene therapy also was not to be driven entirely by the eco-
nomic concerns of the biomedical industry, overlooking rarer
diseases while pushing research to combat more common and
hence more lucrative ones.226 This is a problematical considera-
tion in the traditional European context of socialized
medicine 22 and given the goals of the White Paper.22 8
3. Ethical Review of Somatic Gene Therapy Protocols
and Products
The third part of the Archer Report confirmed that most Eu-
221. ARCHER REPORT, supra note 6, at 5; see Recommendations of Councils, supra note
220, at 1271 (discussing guidelines of the European Medical Research Councils).
222. ARCHER REPORT, supra note 6, at 5.
223. Id.
224. Id. "[T]he interests of the patient's health should always prevail over the re-
search interests." Id.
In addition, informed consent of the patient should be obtained, noting that,
due to the declared uncertainty implicit in experimental treatments, the stan-
dard of disclosure for patient involvement and authorization should be higher
than the standard required for conventional treatments.
Id.
225. Id. at 5.
226. Id. "Special care should be taken of 'orphan diseases' (those affecting few
patients) which are ... given great social support but are of little or no interest to the
medicinal industry." Id.
227. Id. at 6.
228. White Paper, supra note 21.
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ropean regulatory efforts to date have occurred at the various
national levels.2 29 It supported this point by highlighting the
fact that, in considering gene therapy regulation and making
their recommendations, various European advisory bodies did
not look beyond the national level.23 ° After briefly reviewing the
protocols and regulations of the United Kingdom, France, the
Netherlands, Italy, and Germany,23' the Archer Report concluded
that well-considered, Union-wide legislation was desirable,
although some broad EU biotechnology regulations apply to cer-
tain aspects of gene therapy. 2  The Archer Report maintained
that the articulation and implementation of such a framework
would result in a fuller realization of the potential of gene ther-
apy in Europe.233  Reflecting some of the broad goals of the
229. ARCHER REPORT, supra note 6, at 7.
Any somatic gene therapy protocol must be assessed as to the ethical aspects.
The natural places for such assessment are the local research ethics commit-
tees. They are supposed to be advisory bodies, leaving the responsibility of any
accident with the medical team. However, there is a tendency in several Euro-
pean countries, as well as in the United States, to look for a reenforcement of
the action of the local committees by one or more national supervisory bodies.
Id.
230. Id. at 8.
The 1988 Guidelines from the European Medical Research Councils recom-
mend that 'a national body should consider all proposals for human gene
therapy and ensure the application of agreed national guidelines. Early trials
should be monitored by a central body.' Since 1989, the Council of Europe
has recommended 'national or regional multidisciplinary bodies' with tasks of
informing, guiding, monitoring and evaluating results. At the First Round Ta-
ble of Ethics Committees (Madrid, 1992), the Council of Europe suggested
that national ethics committees be consulted as an instance complementary to
the local ethics committees, in regard to formulation of standards, support,
oversight, and evaluation.
Id. (citations omitted).
231. Id. at 7-8; see supra notes 107-33 and accompanying text (discussing disparate
national regulatory efforts in Member States).
232. ARCHER REPORT, supra note 6, at 8.
Directives 90/219/EEC and 90/220/EEC from the European Union apply to
certain phases of gene therapy protocols, but do not cover, for instance, the
clinical trials. These are regulated, in some European countries, by specific
legislation. It might be desirable to have, on this, a legal document at Euro-
pean level.
Id.; see supra notes 138-39 and accompanying text (discussing Directives 90/219 and 90/
220).
233. ARCHER REPORT, supra note 6, at 8.
An important ethical requirement for the whole net of control mechanisms is
that, in addition to the quality of the ethical argument, they are efficient and
do not cause unnecessary delays. Illnesses will not wait for a more convenient
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White Paper, it envisioned involving all citizens of the EU in this
process.23 4
This part of the Archer Report also considered how the
emerging market for gene therapy products would be regu-
lated.235 Given the great market potential of gene therapy prod-
ucts, it emphasized the need for appropriate regulation of man-
ufacturing and marketing efforts.25 6 Certain aspects of research
and commercially manufactured gene therapy products will be
regulated in three ways:23 7 by general Community legislation for
biotechnological products;2 38 by the Code for Good Clinical
Practice for Trials on Medicinal Products in the European Com-
munity;239 and by the marketing authorizations of the EMEA.2 4
The Archer Report also mentioned that additional guidelines
would be issued in the course of 1995.241
time and the patients need any help that can be given to them now. For such
efficiency, the harmonization and partial standardization of all European eval-
uation processes might be helpful.
Id.
234. Id.
Another important ethical requirement is the transparency of the evaluation
processes. They should be regularly published, giving to the public an objec-
tive information on the scientific and ethical aspects of gene therapy develop-
ments, and promoting the close participation of European citizens in the dem-
ocratic construction of our science, technology, and ethics.
Id.
235. Id.
236. Id.
It is expected that, within a 3-5 years period, products for gene therapy are
ready to come on the market. The gene therapy market is expected to be, in
the near future, very large and the economic impact on biomedical equip-
ment and gene therapy consumables will be considerable. It is important,
therefore, that the manufacturing, commercialization, and distribution of
gene therapy products are appropriately regulated.
Id.
237. Id. at 9.
238. See supra notes 138-39 and accompanying text (discussing Council Directive
90/219/EEC on the contained use of genetically modified microorganisms and Coun-
cil Directive 90/220/EEC on the deliberate release of genetically modified organisms
into the environment).
239. ARCHER REPORT, supra note 6, at 9. "This code includes the requirements for
informed consent of the subject taking part in the trial and for the review of the local,
pluridisciplinary and independent ethics committees." Id.
240. See supra notes 143-51 and accompanying text (discussing function and scope
of EMEA regulation).
241. ARCHER REPORT, supra note 6, at 9. "Additional guidelines for specific quality
and safety requirements in the manufacture and control of products for gene therapy
will be available in 1995." Id.
1332 FORDHAMINTERNATIONALLAWJOURNAL [Vol. 18:1303
4. Ethical Evaluation of Germline Gene Therapy
Finally, the fourth part of the Archer Report addressed
germline gene therapy.242 It began by stating that the present
state of knowledge for germline gene therapy is entirely insuffi-
cient.2 14 3 Then, the Archer Report assessed the status of germline
gene therapy along the same four principles it used in its evalua-
tion of somatic gene therapy: benefits, risks, dignity and auton-
omy of the person, and justice.2 "
a. Benefits
In assessing the benefits of germline gene therapy, the
Archer Report first recognized that in a large number of cases
there are easier and safer alternatives. 45 In the remainder of
cases, however, germline gene therapy is the better, if not the
only, alternative.246 As the only technique capable of engender-
ing a genetic change in all the cells of an individual, germline
242. Id. at 10.
243. Id.
The present state of knowledge in germ-line gene therapy can be described as
follows: a) there is no sufficient experience and monitoring of somatic gene
therapy as to clearly establish the safety and effectiveness of its use and, much
less, of its extension to the self-perpetuating germ-line; b) [there] are no suffi-
cient animal studies on germ-line gene therapy applicable to humans; c) there
is not yet any clinically useful and clearly proposed protocol for germ-line
gene therapy, defining, namely, the vectors to be used and the potential target
cells ....
Id.
244. Id.
245. Id. "[F]or the vast majority of the cases, only one of the parents is carrying
the genetic defect. In such cases, it would be easier and safer to select healthy embryos,
by preimplantation diagnosis, than to perform gene therapy on those which carry the
defect." Id.
246. Id. at 10 & n.5 (quoting Pierre M. Lehn, Scientific Aspects of Gene Therapy
35 (forthcoming 1995)).
Only in the highly exceptional and unlikely cases of embryos produced by two
individuals both being recessive homozygous for the same defect would gene
therapy be useful, since all embryos would then be affected. It can be an-
swered, however, that other and more frequent cases in genetics could be
mentioned where preimplantation diagnosis is of no help.... This is the case
of 'parents who do not wish to have heterozygous children in order to spare
them the difficult decisions they would have when they in turn came to have
children'.. . . The same applies to diseases due to mitochondrial gene de-
fects .... Gene therapy of spermatogonia might be the only possible option for
those who have serious ethical objections against preimplantation diagnosis
and destruction of pre-embryos.
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gene therapy is unique and its potential great.2 47 Gene therapy
holds such promise because it can eradicate problems at their
core instead of merely treating their manifestations.2 48  The
Archer Report, therefore, described germline gene therapy as a
"medical imperative." 249
b. Risks
In considering the risks of germline gene therapy, the Archer
Report referred to its evaluation of the present state of knowl-
edge.2 5 0 Hence, it concluded that presently, and for a number
of years to come, the risks could not be evaluated accurately.25'
The Archer Report also noted that the objections of some to
germline gene therapy were based on the technique per se, aside
from a consideration of the risks involved.252
c. Dignity and Autonomy
This portion of the Archer Report was based on the assump-
247. Id. at 11 (quoting COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL
SCIENCES XXIVTH ROUND TABLE MEETING REPORT (1990)).
[G]erm-line [gene] therapy might be 'the only means of treating certain con-
ditions, so continued discussion of both its technical and its ethical aspects is
therefore essential .... The option of germ cell gene therapy must not be
prematurely foreclosed. It may some day offer clinical benefits attainable in
no other way. Science has confounded many predictions about what is techni-
cally possible and what is not. Germ cell therapy might eventually permit
more effective prevention of genetic disease, rather than treatment of its ef-
fects.
Id.
248. Id. "Another benefit is its prophylactic efficiency. By preventing transmission
at the affected genes, germ-line gene therapy would dispense with the need to perform
costly and risky somatic gene therapy in multiple subjects of successive generations." Id.
249. Id. at 11.
The moral mandate of medicine is to cure, to care, and to prevent diseases,
alleviating suffering as much as possible. Considering that such possibility may
be expanded by this self-perpetuating therapy, medicine has a prima facie
moral duty to pursue and employ germ-line gene therapy as soon as it is safe.
Id.
250. Id.
251. Id.
It is clear that without risk evaluation, specially considering that any negative
effects would be indefinitely perpetuated, to start now any attempt of germ-
line therapy in humans would be severely unethical and should be forbidden.
This seems to be an unanimous position of all statements produced on the
matter by a variety of institutions.
252. Id. at 12.
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tion that sufficient research revealed germline gene therapy to
have negligible side-effects in humans.1 3 An ethical evaluation
of germline gene therapy under these circumstances raised im-
portant issues.254 The Archer Report presented the "slippery
slope" argument of some critics of germline gene therapy, envi-
sioning a progression from therapeutic to non-therapeutic uses
of germline gene therapy technology.2 55 The Archer Report also
presented the argument of other critics of germline gene ther-
apy who hold that future generations cannot give their informed
consent and have the right to inherit an unaltered genome. 6
Though guarded, the Archer Report's assessment of germline
gene therapy was more positive than that of the critics of
germline gene therapy.257
d. Justice
Finally, the Archer Report expressed the opinion that
germline gene therapy was not fundamentally objectionable.258
It stated that the relatively unanimous present oppposition to
germline gene therapy was due mostly to the current lack of
knowledge.259 Germline gene therapy on human subjects, there-
fore, was rightfully forbidden.2 °
253. Id.
254. Id.
255. Id. at 13.
256. Id.
257. Id.
It is not clear why hazards of nature should necessarily be better than achieve-
ments of science.... This view overlooks the importance of artificial compo-
nents in our lives and activities. We are artificial beings by our very nature.
The human intelligence and the consequent capability of innovation and crea-
tivity also belong to nature.
Id.
258. Id. at 14.
259. Id.
The only solid reasons to oppose germ-line gene therapy for the time being
are the scientific uncertainties which prevent us from evaluating benefits and
risks. As long as this situation persits, any attempt of performing germ-line
gene therapy in human subjects would be irresponsible and should be forbid-
den. As soon as the situation is scientifically clarified, it will have to be ethi-
cally reevaluated.... [T]he problem will not be insurmountable. In addition,
abuses should not be impeditive of fair uses.
Id.
260. Id.
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III. HARMONIZATION OF GENE THERAPY
REGULATION: RECOMMENDATIONS
Because of its potential, the concerns raised by gene therapy
cannot be allowed to impede its progress. Because of its risks,
however, gene therapy's advances cannot be allowed to proceed
unchecked. The tension between these competing considera-
tions highlights the need for sound regulation of gene therapy,
establishing clear parameters within which researchers, scientific
institutions, and pharmaceutical firms, among others, may oper-
ate. In the absence of such a regulatory framework for gene
therapy, the field's greatest potential in terms of medical and
economic benefits may never be realized. Because comprehen-
sive regulation of gene therapy is not imminent at the level of
the European Union,261 research and clinical efforts will con-
tinue to be regulated mostly at the national level of the individ-
ual Member States.262 Given the resources and efforts of the
United States, 263 the Union may thereby be putting itself at a
serious competitive disadvantage. 2 1 It may also fail to maximize
the medical and economic potential of gene therapy.
A. Effect of the Archer Report
The Archer Report fulfilled its fact-finding purpose of present-
ing the technology of gene therapy and the accompanying is-
sues.2 5 It also recognized the difficulty in reevaluating certain
European health care priorities and in overcoming technologi-
cal disparities among the Member States to make the benefits of
gene therapy equally available to all Europeans. 266 Although the
261. See supra notes 185-86 (discussing Commission's wait-and-see approach).
262. ARCHER REPORT, supra note 6, at 7-8.
263. See supra note 68 and accompanying text (discussing ratio of gene therapy
protocols in United States to gene therapy protocols in European Union).
264. Valerie Szczepanik, Regulation of Biotechnology in the European Community, 24
LAw & POL'Y INT'L Bus. 617, 619-20 (1993) [hereinafter Szczepanik, Regulation].
265. ARCHER REPORT, supra note 6.
266. Id. at 6.
A second problem of justice refers to the distribution of resources for health
care. In contrast to a more utilitarian view in the US, most [Eluropean coun-
tries defend that everybody's right to health care is equal. However, the de-
bates on resource allocation have shown that, due to the fast increasing
number of new biomedical technologies, scarcity of resources is becoming evi-
dent and choices in health care are therefore inevitable. In this same context,
socialized medicine, which is traditional in Europe, has recently given some
place to forms of medical privatization. These problems of choices in health
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Archer Report recognized the need for comprehensive Union-
wide regulation, 267 it did not offer concrete solutions.2 68  The
pace of the research, however, is such that if the European
Union wishes to attain the goals set in the White Paper, capitaliz-
ing on the potential of gene therapy to bring prosperity and
health equally to the citizens of all the Member States, it must
act soon.
B. Need for Thoughtful Regulation
Currently, certain aspects of gene therapy are regulated
within the European Union under some broad biotechnology
Directives, 26 9 the recommendations of the EMEA,27 0 and any ad-
ditional guidelines within the individual Member States. 71
Thus, Council Directives 90/219 and 90/220 will control the
risks presented by certain elements of gene therapy, such as the
viral vectors used to insert functional genes.272 The regulations
of the EMEA will govern the eventual marketing of gene therapy
products.2 73 In part, it will also ensure that citizens of the Union
share equally in the medical benefits of gene therapy.274 The
more fundamental aspects of gene therapy research, however,
are not regulated uniformly and are subject to the guidelines of
care will soon affect gene therapy, specially because this new technology is, at
the moment, still very expensive. Criteria for priorities in health care have to
be globally studied, discusse[d] and established.
Id.; see id. n.3, (citing A REPORT FROM THE DUTCH GOVERNMENTAL COMMITTEE ON
CHOICES IN HEALTH CARE (1992)). The study provides four criteria to be used in consid-
ering whether a given technology is to be considered part of a "basic package" of health
care: 1) Is it necessary care, from the community point of view?; 2) Is it demonstrated to
be effective?; 3) Is it efficient?; and 4) Can it be left to individual responsibility? Id. at 6.
A third problem ofjustice deals with the distribution of gene therapy centers
among the different countries. It would not seem fair that the benefits of this
new technology were restricted to industrialized countries. It would be advisa-
ble to develop a policy for the promotion of gene therapy applications in de-
veloping countries.
Id.
267. Id. at 8.
268. Id.
269. See supra notes 138-39 (discussing Council Directives 90/219 and 90/220).
270. See supra notes 148-51 and accompanying text (discussing function of EMEA).
271. See supra notes 107-33 and accompanying text (discussing regulatory efforts at
national levels).
272. See supra notes 134-39 and accompanying text (discussing regulation of viral
vectors under existing Council Directives).
273. See supra notes 148-51 and accompanying text (discussing role of EMEA).
274. Id.
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the individual Member States.2 75
Thus, researchers throughout the Union are subject to vary-
ing restrictions on their work.2 76 Because scientific institutions,
pharmaceutical firms, and governmental agencies must operate
in accordance with pertinent existing regulations in allocating
resources for gene therapy research, predictable ground rules
and clear regulations could result in more efficient allocations,
accelerating the pace of progress.277 The European Union,
therefore, should enact Union-wide gene therapy regulations to
create the kind of harmonized and streamlined environment in
which academics and industrialists may flourish.
Regulation can also ensure that research is guided by the
proper motives. Without clear uniform Union-wide guidelines,
the Member State with the most permissive regulatory frame-
work may host the bulk of the research initiatives, possibly to the
detriment of the entire endeavor. 78 Ultimately, research must
be driven by the most pressing medical needs, not by profit mo-
tives. 279 The EU should seize the opportunity it now has to affect
the course of the development of gene therapy.
C. Need for Harmonization in the European Union
Given the current levels of infrastructure and investment,
no Member State alone is able to compete with the United States
in the field of gene therapy.2 80 The European Union must,
275. See supra notes 107-33 and accompanying text (discussing regulatory efforts at
national levels).
276. Id.
277. Szczepanik, Regulation, supra note 264, at 645. "For industry to make wise
investment and development decisions, it must be assured of a stable regulatory envi-
ronment." Id.
Perhaps even more affected than industrialists by the EC's [biotechnology]
regulatory scheme are academic researchers, who, unlike their industry coun-
terparts, cannot calculate a profit profile to justify outlay of large amounts of
time and money needed to meet regulatory requirements.... Another effect
will be that only research leading to profit-making will be undertaken, cur-
tailing much-needed basic research with prohibitive costs.
Id. at 641-42.
278. See supra note 218 (discussing risks of backlash).
279. See supra note 226 (defining and discussing orphan diseases).
280. Szczepanik, Regulation, supra note 264, at 620.
The relative freedom of U.S. industry to pursue a variety of courses in the
development of [biotechnology] products also gives the U.S. a comparative
advantage. Historically, European countries have hesitated to invest in bio-
technology, partially because cultural and legal traditions tended not to pro-
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therefore, harmonize the various research efforts within its bor-
ders, avoiding the duplication of trials and encouraging cooper-
ation. To achieve this goal, the field cannot be subject to multi-
pie independent sets of standards.
Individual European pharmaceutical companies and scien-
tific institutions in the leading European states will be able to
remain in the forefront of innovation and to retain a share of
the market for gene therapy products. Biotechnology, and gene
therapy in particular, however, have more to offer the Union. In
terms of research and medical treatment, gene therapy is labor
intensive, potentially employing large numbers of highly skilled
professionals."' The EU must therefore act to ensure its status
as a biotechnology producer, not a mere consumer. Each Mem-
ber State must share the benefits of this technology, its pursuit
elevated and organized above national borders.
Thus, the approach articulated by the Commission in its
communication subsequent to the White Paper is diconcerting s2
Vowing to perform the important function of remaining abreast
of developments in the field, the Commission instead postpones
concrete action. Given Europe's more limited gene therapy re-
search efforts, the Commission should realize the urgency of the
need for orchestration.
D. Taking the Proper Steps Forward
Comprehensive Union-wide regulations for somatic gene
therapy should be articulated, agreed upon, and enforced by the
Member States as soon as possible. Certain codes of conduct
and standards of practice already are widely accepted and could
lay the foundation for this effort."' Beyond this, concrete ef-
forts should be made to orchestrate research efforts in all Mem-
ber States.284 Only then will Europe as a whole be able to re-
mote venture capital formation and, consequently, risk-taking ventures, plac-
ing the EC at a competitive disadvantage from the start. Additionally, govern-
ment funding has been lower in the EC than in the United States ....
281. White Paper, supra note 21, COM (93) 700 Final, at 115, 5.6.
282. Commission Communication, supra note 92, at 7, in COMMISSION DOSSIER, supra
note 92, at 29. "An ongoing review of the biotechnological regulatory framework shall
be carried out as new scientific knowledge and the emerging regulatory practice of
major international competitors indicates that this is necessary or desirable." Id.
283. See supra note 57 and accompanying text (discussing widely-recognized gen-
eral guidelines for clinical research).
284. White Paper supra note 21, COM (93) 700 Final, at 117, 1 5.9. The White
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main competitive and derive the full medical and economic ben-
efits of gene therapy.
CONCLUSION
As outlined in the White Paper, Europe is placing great
hopes on achieving success in the field of gene therapy. The
groundwork to attain the goals of the White Paper has not been
laid, however. To date, regulation of gene therapy, necessary in
structuring the research efforts, has happened haphazardly and
independently within the individual Member States. Thus, on
an issue of great economic and medical importance to all its citi-
zens, the EU stands fragmented where it should stand as one. If
the European Union makes a concerted effort to harmonize its
regulatory framework for gene therapy and to orchestrate its re-
search efforts, however, it has every chance of exploiting the fill
potential of this promising new technology.
Paper, for example, envisages a network of biotechnology science parks throughout the
European Union, linking academic institutions and research laboratories. Id.
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